Contents
Vol 7, Issue 280
Contents
Editorial
- Immunotherapy: Making the case for precision medicine
Immunotherapy illustrates precision medicine’s potential to turn molecular data on human diseases into targeted treatments.
Perspectives
- Therapeutics to block autoantibody initiation and propagation in systemic lupus erythematosus and rheumatoid arthritis
Recent advances in lupus and rheumatoid arthritis suggest new approaches for damping autoimmunity.
- Advances in allergen immunotherapy: Aiming for complete tolerance to allergens
Allergen-specific immunotherapy is a tolerance-inducing therapy for allergic disease.
- Adoptive cellular therapy: A race to the finish line
Engineered T cells are under development in academic-industry partnerships, accelerating the pace toward widespread availability.
State of the Art Review
- On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation
This Review presents the state of research and future outlook on cancer immunotherapy approaches such as immune checkpoint inhibitors.
Review
- Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation
This Review discusses new therapies that may help to prevent or treat graft-versus-host disease and solid organ transplant rejection.
Editors' Choice
- Personalized cancer medicines
An in silico prescription strategy targets genes driving tumorigenesis.
- Good-in-good-out: Diet modification in chronic kidney disease
Low-protein diet with or without ketoacids retards renal failure progression without increasing mortality.
- HIF-1α at the center of the sepsis Yin and Yang
Human monocytes up-regulate hypoxia-inducible factor-1α and acquire an immunosuppressive phenotype in sepsis.
- Preventing an unholy alliance
A repurposed cancer drug blocks a critical interaction between amyloid-β and tau, preventing neuronal damage in mouse models of Alzheimer’s disease.
